Guglielmo Vetere
Assistant Professor - Gastrointestinal Medical Oncology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2026
Year:
2026
PURPOSE The prevalence and death rates of early-onset colorectal cancer (EOCRC) have been increasing at an alarming rate since 1994. Compared with late-onset colorectal cancer (LOCRC), EOCRC is more aggressive and resistant to treatment. Despite KRAS mutations and the mitogen-activated protein kinase/extracellular signal-related kinase (MAPK/ERK) pathway's significant role in colorectal cancer tumorigenesis and progression, these mutations are less frequent in patients with EOCRC. METHODS In this study, we conducted proteotranscriptomic profiling of two independent cohorts (MD Anderson for testing and The Cancer Genome Atlas for validation), comparing EOCRC and LOCRC tumors. Our focus was on sporadic, microsatellite-stable, treatment-naïve patients with early-onset ( 60 years) colorectal adenocarcinomas. RESULTS Our analysis revealed consistent molecular differences between EOCRC and LOCRC, particularly in pathway enrichment profiles. The two pathways with the highest levels of significant gene set enrichment analysis in EOCRC tumors were the downregulation of epithelial-mesenchymal transition and upregulation of Wnt/β-catenin signaling pathways. Both testing and validation cohorts showed a consistent enrichment in hallmark KRAS signaling. However, using the novel KRAS-ERK gene signatures to better capture the pathway signaling functionality, we identified a consistent upregulation of MAPK signaling specifically in EOCRC tumors. Further analysis of this enrichment in wild-type RAS GTPase ( KRAS , NRAS , and HRAS ) tumors confirmed significant MAPK upregulation in EOCRC wild-type RAS tumors ( P < .001). Proteomic analysis further supported these transcriptomic findings, reinforcing the molecular distinctions in EOCRC. CONCLUSION This study not only elucidates the unique molecular attributes of EOCRC but also lays the groundwork for exploring MAPK-targeted therapies specifically for this age group. Given the increasing prevalence of EOCRC, our findings highlight the need for larger investigations into MAPK upregulation in EOCRC and its potential as a target for precision therapies.
Year:
2025
Background: Encorafenib plus cetuximab (EC) is the standard of care for pre-treated BRAF V600E mutated metastatic colorectal cancer (mCRC). Depth of response (DpR) and early tumour shrinkage (ETS) previously showed a strong correlation with survival outcomes of first-line chemotherapy ± biological agents. Objectives: We aimed to assess potential predictors of primary resistance to EC ± binimetinib (B) and relationships of DpR/ETS with survival outcomes and clinical characteristics. Design: This is a retrospective real-world cohort study of BRAF V600E mutated mCRC patients treated with second-line EC ± B at 20 Italian centres. Methods: Measurable disease according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 at baseline and at least one subsequent computed tomography (CT) scan were mandatory for inclusion. Clinical features associated with primary resistance, DpR and ETS were investigated. Relationships of DpR and ETS, both as binary, according to conventional (30% for DpR and 20% for ETS) and median cut-off values, and continuous variables, with progression-free (PFS), overall survival (OS) and duration of response (DoR) were assessed in non-primary resistant patients. Results: A total of 105 patients were included. The primary resistance rate was 28% (29/105) and was associated with baseline peritoneal metastases ( p = 0.04). Disease control and overall response rates were 72% (76/105) and 24% (25/105), respectively, with a median DpR of 15% and an ETS rate of 37% (28/76). Mucinous histology was associated with a significantly lower magnitude of DpR ( p = 0.005) and a lower rate of ETS ( p = 0.002). In the multivariable models, DpR significantly correlated with longer PFS as a dichotomous variable, according both to conventional (hazard ratio (HR) DpR ⩾ 30% : 0.52, 95% CI: 0.30–0.90, p = 0.02) and median cut-off values (HR DpR⩾15% : 0.55, 95% CI: 0.33–0.92, p = 0.03), and as a continuous variable (HR per 10% increment: 0.88, 95% CI: 0.78–0.98, p = 0.02), while correlations with OS were not confirmed. DpR was also significantly associated with longer DoR ( p DpR⩾30% = 0.04; p DpR⩾15% = 0.04; p cont. = 0.02), whereas no relationships of ETS with PFS, OS or DoR were detected. Conclusion: A DpR of at least 15% independently predicts PFS benefit in BRAF V600E mutated mCRC patients treated with second-line EC ± B.
Year:
2025
Year:
2024
PURPOSE KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials in solid tumors including mCRC. We aimed at performing a comprehensive characterization of clinical, molecular, immunologic, and prognostic features of KRASG12D-mutated mCRC to inform the design and the interpretation of future trials. METHODS We performed a pooled analysis of phase III TRIBE and TRIBE2 studies comparing 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (bev) to doublets (5-fluorouracil, leucovorin, and oxaliplatin or 5-fluorouracil, leucovorin, and irinotecan)/bev. RESULTS One hundred and thirty-six (16%) of 854 patients with available KRASG12D mutational status were KRASG12D mutated. KRASG12D-mutated patients had more frequently right-sided primary tumor and were less likely to present liver-only metastases with respect to other RAS mutated and all-wild-type (wt) patients. Compared with the BRAFV600E-mutated group, KRASG12D-mutated patients had more frequently left-sided primary tumor, resected primary tumor at the time of diagnosis, and Eastern Cooperative Oncology Group performance status 0. KRASG12D-mutated patients had better prognosis than BRAFV600E-mutated and worse prognosis than all wt patients. No prognostic difference was evident between KRASG12D mut and other RAS mut patients overall or according to other specific KRAS or NRAS hotspot mutations. No interaction effect was observed between KRASG12D mut and the benefit provided by FOLFOXIRI/bev compared with doublets/bev. PIK3CA mut were reported more frequently among KRASG12D-mutated tumors compared with both other RAS mut and all wt. CONCLUSION A detail estimation of KRASG12D mut mCRC patients' characteristics and expected outcomes may be useful when planning future studies in this subgroup. The high prevalence of PI3K/PTEN/Akt pathway activating alterations may affect the efficacy of targeted strategies.
Year:
2024
Background and Aims The best adjuvant chemotherapy for resected biliary tract cancer (BTC) is under debate, with capecitabine supported by weak evidence. Aim of this network meta‐analysis is to estimate the efficacy of different phase II/III regimens, comparing monotherapies (gemcitabine or fluoropyrimidines) head‐to‐head, against observation and combination regimens. Methods A comprehensive literature search was conducted on PubMed and EMBASE for phase II/III randomized clinical trials (RCTs) available as of December 2023, reporting hazard ratios (HRs) of overall survival (OS) and event‐free survival (EFS). A frequentist framework employing a random‐effects model was applied; treatment rankings were outlined according to P ‐score, based on direct and indirect evidence. Exploratory subgroup analyses for OS were also performed (primary site, resected margin status and nodal involvement). Results Six RCTs (1979 total patients) were identified. Fluoropyrimidine monotherapy showed significantly better OS (HR .84 [.72–.97]) and EFS (HR .79 [.69–.91]) than observation, as any monotherapy did (HR .84 [.74–.96]; HR .79 [.70–.89]). In the head‐to‐head comparison for OS, only S1 confirmed to be superior to observation alone (HR .69 [.49–.98]) while fluoropyrimidines achieved the best P score (.81), similarly to any monotherapy (0.92). Combinations failed to prove superior to monotherapies with respect both to OS and EFS. Subgroup analyses were inconclusive due to results' inconsistency and limited sample size. Conclusions Our work confirmed that adjuvant chemotherapy grants OS and EFS benefit for resected BTC patients. Fluoropyrimidines appeared the most effective option, confirming capecitabine as the preferred choice for the Western population.
Year:
2024
Year:
2024
Background: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and survival outcomes in metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC). Objectives: This study aims to investigate and elucidate the relationship between malignant ascites, PM and survival outcomes in both mCRC and mGC patients. Design: This is a retrospective analysis of prospectively collected clinical trial data of mCRC and mGC patients with PM. Methods: We performed two pooled analyses, firstly of two Italian randomized trials enrolling patients with mCRC eligible for systemic therapy (TRIBE2; VALENTINO), and secondly of gastric cancer and peritoneal metastasis (GCPM) patients who underwent bi-directional therapeutic treatment comprising systemic and peritoneal-directed therapies. Results: Of 900 mCRC patients, 39 (4.3%) had PM with malignant ascites. Compared to the group without PM, median progression-free and overall survival were significantly inferior in the ascites group (hazard ratio (HR) for progression-free survival (PFS) 1.68, 95% confidence interval (CI): 1.21–2.35, p = 0.007; HR for overall survival (OS) 2.14, 95% CI: 1.57–3.01, p < 0.001), but not in the group of PM without ascites (HR for PFS 1.10, 95% CI: 0.91 – 1.34; HR for OS 1.04, 95% CI: 0.84 – 1.30). Of 170 patients with GCPM, those with ascites had higher median Peritoneal Cancer Index scores (23 vs 9, p < 0.001). Median OS was significantly inferior among those with ascites compared to those without (13.0 vs 21.0 months, HR 1.71, 95% CI: 1.16–2.52, p = 0.007). Conclusion: Ascites identifies a subgroup of patients with PM and poor outcomes, for whom tailored research are needed.
Year:
2024
Purpose: Microsatellite instability (MSI) is currently the only predictive biomarker of efficacy of immune checkpoint inhibitors (ICI) in metastatic colorectal cancers (mCRC). However, 10-40% of patients with MSI mCRC will experience a primary resistance to ICI. Experimental design: In 2 cohorts of patients with MSI mCRC treated with ICI (exploratory: N=103, validation: N=35), 3’RNAseq was performed from primary tumors. Previously described single-cell transcriptomic signatures of tumor microenvironment (TME) were analysed. Results: In the exploratory cohort, the unsupervised clustering allowed the identification of three clusters of tumors with distinct transcriptional profiles: cluster A (“stromal HIGH -proliferation LOW ”), cluster B (“stromal HIGH -proliferation MED ”), and cluster C (“stromal LOW -proliferation HIGH ”), with an enrichment of patients progressing at first disease assessment under ICI in the cluster A (30% vs 12% in cluster B and 8.1% in cluster C, p=0.074). Progression-free survival (PFS) was also significantly shorter in patients belonging to cluster A, compared to clusters B or C (p HIGH -proliferation LOW ” cluster is associated with a poorer prognosis with ICI treatment.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (21)
Raghav Sundar
Associate Professor
Yale University
David J. Pinato
Imperial College London
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Aurélien de Reyniès
PU-PH (biologie cellulaire) / Professeur
Université Paris Cité
nicola valeri
Reader and Team Leader
Institute of Cancer Research
PAOLA VIGNALI
University of Pisa
Alessio Cortellini
Imperial College London
Ian Chau
Royal Marsden Hospital Sutton
Michael White
Assistant Professor
-
Michele Ghidini
Docenti di ruolo di IIa fascia
University of Insubria
Luca Magnani
Docenti
University of Milan
Matteo Fassan
Docenti di ruolo di Ia fascia
University of Padova
Naureen Starling
Reader
Institute of Cancer Research
Emerik Osterlund
Uppsala Universitet Farmaceutiska fakulteten
julien taieb
Professor Head of the department
Université Paris-Saclay
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Chiara Braconi
Chair in HepatoBiliary Oncology
University of Glasgow
David Cunningham
Professor Cancer Medicine
Institute of Cancer Research
Pierre Laurent-Puig
Université Paris Descartes
Chiara Cremolini
University Hospital of Pisa
Antonia Martinetti
Fondazione IRCCS Istituto Nazionale dei Tumori
Make your next move.
Prepare your application
Review drafts before you send them.